Publications

PUBLICATIONS

By clicking on the link in the journal name, you are directed to the manuscript.

Natural Killer cells

  1. Beelen NA, Aberle MR, Bruno V, Olde Damink SWM, Bos GMJ, Rensen SS, Wieten L. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Front Immunol. 2023 Jul 14;14:1133796.
  2. Ehlers FAI, Mahaweni NM, van de Waterweg Berends A, Saya T, Bos GMJ, Wieten L. Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages. Cancer Immunol Immunother. 2023 Jun;72(6):1789-1801.
  3. Beelen NA, Ehlers FAI, Kooreman LFS, Bos GMJ, Wieten L. An in vitro model to monitor natural killer cell effector functions against breast cancer cells derived from human tumor tissue. Methods Cell Biol. 2023;173:133-153.
  4. Beelen NA, Ehlers FAI, Bos GMJ, Wieten L. Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell‑mediated antibody‑dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunol Immunother. 2023 Apr;72(4):797-804.
  5. Ehlers FAI, Beelen NA, van Gelder M, Evers TMJ, Smidt ML, Kooreman LFS, Bos GMJ, Wieten L. ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response. Cancers. June 2021; 13, 3232.
  6. Gong Y, Klein Wolterink RGJ, Gulaia V, Cloosen S, Ehlers FAI, Wieten L, Graus YF, Bos GMJ, Germeraad WTV. Defucosylation of tumor-specific humanized anti-MUC1 monoclonal antibody enhances NK cell-mediated anti-tumor cell Cytotoxicity. Cancers, May 2021, 13, 2579.
  7. Ehlers FAI, Mahaweni NM, Olieslagers TI, Bos GMJ, Wieten L. Activated natural killer cells withstand the relatively low glucose concentrations found in the bone marrow of multiple myeloma patients. Front Oncol. May 2021, 622896.
  8. Gong Y, Klein Wolterink RJG, Wang JX, Bos GMJ, Germeraad WTV. Generation chimeric antigen receptor Natural Killer cells for tumor immunotherapy. J Hematol Oncol. 2021. 14:73.
  9. Van Elssen C, van Gorkom G, Voorter C, von dem Borne P, Meijer E, Wieten L, Bos G. Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors. Ann Hematol. 2021 Jan;100(1):181-187.
  10. Gong Y, Klein Wolterink RGJ, Janssen I, Groot AJ, Bos GMJ, Germeraad WTV. Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor. Mol Ther Methods Clin Dev. 2020 Jun 12; 17: 634–646.
  11. Mahaweni NM, Ehlers FAI, Bos GMJ, Wieten L. Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A. Front Immunol. 2018 Dec 4;9:2848.
  12. Mahaweni NM, Ehlers FAI, Sarkar S, Janssen JWH, Tilanus MGJ, Bos GMJ, Wieten L. NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment. Front Immunol. 2018 Jun 22;9:1415.
  13. Mahaweni NM, Bos GMJ, Mitsiades CS, Tilanus MGJ, Wieten L. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions. Cancer Immunol Immunother. 2018 Jun;67(6):861-872.
  14. van Gelder M, Vanclée A, van Elssen CHMJ, Hupperets P, Wieten L, Bos GMJ. Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer. Breast Cancer Res Treat. 2017 Feb;161(3):421-433.
  15. Sarkar S, Noort W, Van Elssen CHMJ, Groen R, van Bloois L, van Gelder M, Schouten HC, Tilanus MGJ, Germeraad WTV, Wieten L, Martens ACM, Bos GMJ. Alloreactive natural killer cells have anti‐tumor capacity against disseminated human multiple myeloma in Rag2-/-γC-/-mice when combined with low dose cyclophosphamide and total body irradiation. J Mol Cytotherapy 2015 Sept; 1: 001.
  16. Sarkar S, van Gelder M, Noort W, Xu Y, Rouschop KM, Groen R, Schouten HC, Tilanus MGJ, Germeraad WTV, Martens ACM, Bos GMJ, Wieten L. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol Immunother. 2015 Aug;64(8):951-63.
  17. Huijskens MJAJ, Walczak M, Sarkar S, Atrafi F, Senden-Gijsbers BLMG, Bos GMJ, Wieten L, Germeraad WTV. Ascorbic acid promotes proliferation of NK cell populations in culture systems applicable for NK cell therapy. Cytotherapy. 2015 May;17(5):613-20.
  18. Wieten L, Mahaweni NM, Voorter CE, Bos GMJ, Tilanus MGJ. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens. 2014 Dec;84(6):523-35.
  19. Sarkar S, Germeraad WTV, Rouschop KM, Steeghs EM, van Gelder M, Bos GMJ, Wieten L. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One. 2013 May 28;8(5):e64835.
  20. Frings PW, Van Elssen CH, Wieten L, Matos C, Hupperets PS, Schouten HC, Bos GMJ, van Gelder M. Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice. Breast Cancer Res Treat. 2011 Dec;130(3):773-81.
  21. Vanclée A, van Gelder M, Schouten HC, Bos GMJ. Graft-versus-tumor effects on murine mammary carcinoma in a model of nonmyeloablative haploidentical stem cell transplantation. Bone Marrow Transplant. 2006 Jun;37(11):1043-9.
  22. Vanclée A, Lutgens LC, Oving EB, Deutz NE, Gijbels MJ, Schouten HC, Bos GMJ.Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant. 2005 Nov;36(10):907-15.

Dendritic cells

  1. Oth T, Habets THPM, Germeraad WTV, Zonneveld MI, Bos GMJ, Vanderlocht J. Pathogen recognition by NK cells amplifies the pro-inflammatory cytokine production of monocyte-derived DC via IFN-γ. BMC Immunol. 2018 Feb 13;19(1):8.
  2. Oth T, Vanderlocht J, Van Elssen CH, Bos GMJ, Germeraad WTV. Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination. Mediat Inflammat: 2016;2016:5740373.
  3. Oth T, Van Elssen CH, Schnijderberg MC, Senden-Gijsbers BL, Germeraad WT, Bos GM, Vanderlocht J. Potency of Both Human Th1 and NK Helper Cell Activation is Determined by IL-12p70-Producing PAMP-Matured DCs. J Interferon Cytokine Res. 2015 Sep;35(9):748-58.
  4. Oth T, Schnijderberg MC, Senden-Gijsbers BL, Germeraad WT, Bos GM, Vanderlocht J. Monitoring the initiation and kinetics of human dendritic cell-induced polarization of autologous naive CD4+ T cells. PLoS One. 2014 Aug 21;9(8):e103725.
  5. Van Elssen CHJM, Oth T, Germeraad WT, Bos GM, Vanderlocht J. Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin Cancer Res. 2014 Mar 1;20(5):1095-103. Review.
  6. Van Elssen CHJM, Vanderlocht J, Oth T, Senden-Gijsbers BLMG, Germeraad WTV and Bos GMJ. Inflammation restraining effects of Prostaglandin E2 on DC-NK interaction are imprinted during DC maturation. Blood. 2011; 118 (9): 2473-2482.
  7. Van Elssen CMJM, Vanderlocht J, Frings PWH, Senden-Gijsbers BLMG, Schnijderberg MCA, Gelder M van, Meek B, Libon C, Ferlazzo G, Germeraad WTV and Bos GMJ. Klebsiella pneumoniae triggered DCs recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells. Eur. J. Immunol. 2010. 40: 3138–3149.
  8. Vanderlocht J, Van Elssen CMJM, Senden-Gijsbers BLMG, Meek B, Cloosen S, Libon C, Bos GMJ and Germeraad WTV. Increased tumor-specific CD8+ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma. Int J Immunopathol Pharmacol. 2010; 23 (1): 35-50.
  9. Cloosen S, Arnold J, Thio M, Bos GMJ, Kyewski B, and Germeraad WTV. Expression of tumor-associated differentiation antigens CEA and MUC1 glycoforms in human thymic epithelial cells: 2implications for self-tolerance and tumor therapy. Cancer Res. 67(8): 3919-3926, 2007.
  10. van Leeuwen EBM, Cloosen S, Senden-Gijsbers BLMG, Germeraad WTV and GMJ Bos. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector. Cytotherapy 8, 1, 24-35, 2006.
  11. van Leeuwen EBM, Cloosen S, Senden-Gijsbers BLMG, Germeraad WTV and GMJ Bos. Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC. Cytotherapy 8, 1, 36-46, 2006.
  12. Cloosen S, Thio M, Vanclee A, van Leeuwen EBM, Senden-Gijsbers BLMG, Oving EBH, Germeraad WTV and GMJ Bos. Mucin-1 is expressed on mature dendritic cells, both in vitro and in vivo. Int Immunol. 16(11): 1561-1571, 2004.